Fibrocell Science (FCSC) Reports Q2 Loss of $1.03
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Fibrocell Reports Second Quarter 2018 Financial Results and Recent Highlights
August 9, 2018 8:00 AM EDTEXTON, Pa., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today reported financial results for the second quarter ended June 30, 2018 and recent operational highlights. Fibrocell will host a conference call and webcast today at 8:30 a.m. EDT.
During the second quarter of 2018, we attained important milestones that continue to advance the development of our gene therapy candidates for rare and devastating conditions affecting the skin and connective tissue, said John Maslowski,... More
